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Abstract  Ubiquitin-conjugating enzyme E2L6 (UBE2L6) is a critical enzyme in ISGylation, a post-translational protein modification that conjugates the ubiquitin-like modifier, interferon-stimulated gene 15 (ISG15), to target substrates.  Previous gene expression studies in acute promyelocytic leukemia (APL) cells showed that all-trans-retinoic acid (ATRA) altered the expression of many genes, including UBE2L6 (200-fold) and other members of the ISGylation pathway. Through gene expression analyses in a cohort of 98 acute myeloid leukemia (AML) patient samples and in primary neutrophils from healthy donors, we found that UBE2L6 gene expression is reduced in primary AML cells compared to normal mature granulocytes. To assess if UBE2L6 expression is important for leukemic cell differentiation – two cell line models were employed. The human APL cell line NB4 and its ATRA-resistant NB4R counterpart, as well as the ATRA sensitive human AML HL60 cells along with their ATRA-resistant subclone – HL60R. ATRA strongly induced UBE2L6 in NB4 APL cells and in ATRA-sensitive HL60 AML cells, but not in the ATRA-resistant NB4R and HL60R cells. Furthermore, short hairpin (sh)RNA-mediated UBE2L6 depletion in NB4 cells impeded ATRA-mediated differentiation, suggesting a functional role for UBE2L6 in leukemic cell differentiation. In addition, ATRA induced 
ISG15 gene expression in NB4 APL cells, leading to increased levels of both free ISG15 protein and ISG15 conjugates. UBE2L6 depletion attenuated ATRA-induced ISG15 conjugation. Knockdown of ISG15 in NB4 APL cells inhibited ISGylation and also attenuated ATRA-induced differentiation.In summary, we demonstrate the functional importance of UBE2L6 in ATRA induced neutrophil differentiation of APL cells and propose that this may be mediated by its catalytic role in ISGylation. 
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ISG15 is a 15kDa protein, which contains 2 UBL domains that share 33% and 32% homology with ubiquitin (Sgorbissa and Brancolini, 2012). The conjugation of ISG15 to substrate lysine residues, known as ISGylation, relies on a narrow range of E1, E2 and E3 enzymes (Supplementary Figure 1). Ubiquitin-like modifier activating enzyme 7 (UBA7/UBE1L) is the E1 enzyme of ISGylation (Jeon et al., 2010). Ubiquitin/ISG15-conjugating enzyme E2 L6 (UBE2L6) operates as an E2 enzyme for both ISGylation and ubiquitination (Jeon et al., 2010). Three known E3 ligases determine ISGylation targets, over 300 of which have been proposed (Jeon et al., 2010; Sgorbissa and Brancolini, 2012). HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase 5 (HERC5) is the dominant E3 for ISGylation and associates with ribosomes to target newly synthesized proteins in a non-specific manner (Durfee et al., 2010). Tripartite Motif Containing 25 (TRIM25) and Ariadne RBR E3 Ubiquitin Protein Ligase 1 (HHAR1) show specificity for 14-3-3 and 4EHP respectively (Sgorbissa and Brancolini, 2012). Ubiquitin Specific Peptidase 18 (USP18) removes ISG15 from its substrates and thus negatively regulates the ISGylation pathway (Malakhov et al., 2002). The precise functions of ISGylation remain under investigation and may be contextual. All components of the system are induced on Type I interferon stimulation suggesting a functional role in anti-viral responses (Sgorbissa and Brancolini, 2012). Free ISG15 has interferon-stimulating cytokine activity when secreted outside of the cell (Bogunovic et al., 2013).
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2.0 Materials and Methods
2.1 Cell lines & culture conditionsThe human APL cell line NB4 and its ATRA-resistant NB4R counterpart were kindly gifted by Dr. B.E. Torbett and Prof. P. Paolo-Pandolfi respectively. ATRA-sensitive human M2 AML HL60 cells were obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Germany). Their ATRA-resistant subclone, HL60R cells were kindly gifted by Dr. Mario Tschan. All cell lines were maintained in RPMI 1640 (Sigma R8758) medium supplemented with 10% fetal calf serum (Sigma F7524) and 1% Penicillin/Streptomycin (Gibco 15070-063) in a humidified atmosphere containing 5% CO2 at 37°C. For differentiation experiments, cells were seeded at 0.2 x 105 cells/mL and treated for 4 days with 1μM ATRA (Sigma R2625) diluted from a 1mM stock in 100% ethanol. 
2.2 Patient studyA cohort of 98 AML patient samples, collected through the HOVON/SAKK (Dutch-Belgian Hematology-Oncology / Swiss Group for Clinical Cancer Research Cooperative Group) protocols 04, 04A, 29 and 42 between 1987 and 2006, were provided by Drs. P. Valk and B. Lowenberg. Patient characteristics have been previously outlined (Schlafli et al., 2012). Primary neutrophils from healthy donors were isolated using polymorphprep (AXIS-SHIELD, Switzerland). All patients provided written informed consent in accordance with the Declaration of Helsinki. 
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avoid genomic DNA signaling and gene expression amplicons were validated with sequencing at the Genomics Resources Core Facility, WCMC. Sequences of specific primers were: UBE2L6_F CTGGAAGCCTTGCACCAAGA, UBE2L6_R GAACATGAGTTAGGAGGGCCG, ISG15_F GGTGGACAAATGCGACGAAC, ISG15_R TCGAAGGTCAGCCAGAACAG. The transcript levels in biological replicates (n=3) were normalized to hPRT transcript levels and relative differences were calculated using the Pfaffl method. Graphical displays and measurements of statistical significance were perfomed on GraphPad prism software. 
2.4 Lentiviral shRNA transductionpLKO.1 lentiviral vectors expressing small hairpin shRNAs targeting both UBE2L6 and ISG15 were purchased from Sigma-Aldrich along with a non-targeting shRNA control (SCH002) in bacterial glycerol stocks. For each gene, five shRNAs were initially tested for efficiency by measuring mRNA levels by qPCR and two shRNAs were then selected for use in further experiments. (shUBE2L6_499 = NM_004223.3-499s1c1/ TRCN0000007284, shUBE2L6_1082 = NM_004223.3-1082s1c1/ TRCN0000007281, shISG15_319 = NM_005101.3-319s21c1/ TRCN0000237825 and shISG15_352 = NM_005101.3-352s21c1/ TRCN0000237824). Lentiviral production and transduction was performed as previously described (Tschan et al., 2003). All vectors contain a puromycin resistance gene and transduced cell clones were selected for 4 days using 1.5 g/ml puromycin.
2.5 Morphology examination Cells were cytospun onto glass slides and stained with Rapi-Diff (Braidwood Laboratories 22007, 22008, 22009) according to product guidelines. Morphology was examined using an Olympus DP70 digital microscope at 400X magnification (Mason Technology, Ireland).
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Entellan (Merck 1076910100). NBT positive cells were then examined, counted in triplicate and presented accordingly. 
2.7 Western blottingCellular protein extracts were lysed in modified RIPA buffer (50 mM TrisHCl - pH 7.4, 150 mM NaCl, 0.25% sodium deoxycholate, 1% Igepal, 1 mM EDTA, 1x Pefabloc, 1x Protease inhibitor cocktail, 1 mM Na3VO4, 1 mM NaF). Protein samples were separated on NuPAGE 4-12%, Bis-Tris gels (Invitrogen NP0322) and electrophoretically transferred onto PVDF membranes (Invitrogen IB401001). Primary antibodies were: anti-UBE2L6 (Abgent AP2118A), anti-ISG15 (Proteintech 15981-1-AP) and anti-β-ctin (Sigma A5441). Proteins were visualized using relevant IR-DYE secondary antibodies and quantified on the Odyssey IR imaging system (Li-Cor, Cambridge, UK). 
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3.0 Results
3.1 UBE2L6 is induced during the neutrophil differentiation of leukemic cellsWe have previously examined the gene expression changes induced by ATRA in APL cells by sequencing RNA extracted from NB4 cells treated with 1μM ATRA for 72h alongside untreated controls (Orfali N, 2019).  These data showed that ATRA, induced a 200-fold increase in UBE2L6 expression. Other members of the ISGylation pathway were also found to be co-regulated (RNAseq data reproduced in Table 1). As NB4 cells respond to ATRA by differentiating towards mature neutrophils, this prompted us to question whether UBE2L6 expression is important for leukemic cell differentiation. We first examined UBE2L6 mRNA expression in 98 primary AML patient samples (M0-M4), 6 samples of normal CD34+ (HSC) cells and in 24 donated mature granulocyte samples using a TaqMan Low Density Array. Relative UBE2L6 mRNA levels are shown as differences in Ct-values as compared to mRNA levels for the housekeeping genes HMBS and 
ABL1. Expression was significantly lower in AML patient samples and HSC cells than in granulocytes, suggesting that increased expression may be important for the mature granulocyte phenotype (Mann Whitney U test, ****p ≤ 0.0001) (Fig. 1A). To test this hypothesis further, we treated NB4 cells with ATRA along with their ATRA-resistant counterparts NB4R cells. We measured UBE2L6 expression by quantitative real-time (q)PCR at 72h, assessing Ct values relative to the housekeeping gene hPRT. Validating our earlier RNA sequencing observations we detected a 180-fold increase in 
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3.2 Knockdown of UBE2L6 inhibits ATRA-induced neutrophil differentiation of NB4 APL 
cellsIn order to investigate whether UBE2L6 has a functional role in leukemic cell differentiation, we generated UBE2L6 knockdown NB4 cells using a lentiviral delivery system to deliver target-specific shRNA. NB4 cells transduced with a non-targeting shRNA were used as a control (SHC). Functional knockdown was confirmed by detecting reduced UBE2L6 protein levels following ATRA treatment in two knockdown clones: shUBE2L6_499 and shUBE2L6_1082. Superior knockdown efficiency is evident in shUBE2L6_1082 (Fig. 2A).  ATRA-induced neutrophil differentiation was reduced in UBE2L6 knockdown NB4 clones compared to control cells. At a transcript level, we detected reduced expression of Granulocyte Colony Stimulating Factor Receptor (GCSFR), a marker of neutrophil differentiation, by qPCR at 72h (*p = 0.0123, ***p = 0.0004) (Fig. 2B).  At a protein level, surface CD11b expression was reduced in ATRA treated knockdown cells when analyzed by flow cytometry at 72h. A direct correlation was observed between UBE2L6 knockdown efficiency and detectable CD11b levels, with both shUBE2L6_499 and shUBE2L6_1082 showing a significant reduction in CD11b (**p = 0.0017 and p = 0.0067, respectively) (Fig. 2C). Morphologically, ATRA treated control cells displayed characteristic features of granulocytic differentiation with increased cytoplasmic volume and visible nuclear indentation (Fig. 2D lower left panel, arrows). This phenotype was stunted in knockdown clones (Fig. 2D lower middle and right panels). Finally we assessed functional differentiation using the Nitro Blue Tetrazolium (NBT) assay, which tests the reducing power of the neutrophil enzyme alkaline phosphatase. We observed and quantified a decreased NBT reduction in UBE2L6 knockdown clones (** p = 0.0069, * p = 0.0354), with a direct correlation again seen between knockdown efficiency and functional differentiation (Fig. 2E (i) lower panels & Fig. 2E (ii)). Together these results demonstrate that UBE2L6 depletion impedes ATRA-mediated granulocytic differentiation of APL cells and prompted us to question the potential mechanism involved in this differentiation block. 
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As described earlier, UBE2L6 is an E2 ligase critical in the conjugation of ISG15 to target proteins during ISGylation, a process with an unknown role in leukemic cell differentiation. A search of UBE2L6 human protein interactions on the publicly available STRING database (Search Tool for the Retrieval of Interacting Genes/Proteins)(www.string-db.org) (Franceschini et al., 2013) depicts a high confidence of interaction between UBE2L6 and ISG15, as well as interactions with the E1 and all E3 ligases of the ISGylation pathway (Fig. 3A). We tested levels of both free and conjugated ISG15 protein in UBE2L6 knockdown NB4 cells using western blot analysis. We found a prominent induction of free ISG15 protein following ATRA treatment in control cells and in knockdown clones.  Notably, conjugated ISG15 was markedly increased after 72h of ATRA treatment in control cells but was impaired in UBE2L6 knockdown cells, with the most efficient knockdown clone shUBE2L6_1082 having the least amount of visible conjugates (Fig. 3B (i) & (ii)). 
3.4 ISG15 is induced during the neutrophil differentiation of leukemic cellsOur RNA sequencing data showed a 17.54-fold increase in ISG15 gene expression in NB4 cells with ATRA treatment (Orfali N, 2019) (Table 1).  We validated this finding by qPCR measurement of ISG15 expression in ATRA treated NB4 cells at 72h, which showed a 23-fold increase in expression in differentiating cells (****p ≤ 0.0001). No significant change in expression was found in ATRA treated NB4R cells (Fig. 4A). HL60 cells undergoing differentiation with ATRA treatment showed a four-fold induction of ISG15 at 96h (**p = 0.0011) whereas no induction was seen in HL60R cells (Fig. 4B). These findings associate ISG15 induction with leukemic cell differentiation rather than solely with ATRA treatment.  
3.5 Knockdown of ISG15 inhibits ATRA-induced neutrophil differentiation of NB4 APL 
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4.0 DiscussionOur results demonstrate that UBE2L6 is under-expressed in AML cells compared to their mature myeloid counterparts. Using two cell line models of AML cell differentiation, we show that cells undergoing ATRA-mediated neutrophil differentiation strongly induce 
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 An inhibitory effect on ATRA-mediated neutrophil differentiation of NB4 APL cells as a direct result of shRNA depletion of either UBE2L6 or ISG15 has not been previously reported. Our findings propose a functional role for these genes in differentiation. We have previously reviewed the effects of ATRA on the PML-RARα protein in APL cells (Orfali et al., 2014). Briefly, in addition to de-repressing transcription, ATRA induces the degradation of the PML-RARα oncoprotein through caspase-3 mediated cleavage, ubiquitin/proteasome mediated proteolysis and through lysosomal-mediated autophagy (Orfali et al., 2014). Investigating a temporal correlation between the reduction in PML-RARα and an induction of UBE1L in ATRA treated NB4 cells, Shah et. al. reported ISGylation of the PML domain of 
PML-RARα with subsequent repression. This repression was opposed by the overexpression of USP18 (Shah et al., 2008).  Subsequent work showed that knockdown of USP18 destabilized PML-RARα and promoted apoptosis in NB4 APL cells but did not have an effect on differentiation (Guo et al., 2010).  A similar destabilizing effect of ISGylation on a leukemic oncoprotein is suggested for the BCR-ABL kinase that drives chronic myeloid leukemia (CML). The expression of BCR-ABL in mouse bone marrow cells results in splenomegaly and an abnormal myeloproliferation resembling CML. Bone marrow cells harvested from USP18-/- mice and transfected with BCR-ABL prior to transplantation into wild-type recipient mice, developed a CML-like state in only 40% of cases, whereas all mice transplanted with USP18+/+ BCR-ABL expressing cells developed disease (Yan et al., 2007). Degradation of 
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promoting ISGylation may prove to have similar benefits. Inhibiting USP18, the negative regulator of ISGylation, has been shown in both cell line and in vivo systems to enhance ISG15 conjugation (Ketscher et al., 2015). A small molecule inhibitor of this isopeptidase is awaited and will greatly advance study in this arena (Basters et al., 2012). 
5.0 ConclusionsWe have identified a novel function of UBE2L6 in the granulocytic differentiation of APL cells, mediated by ISGylation. Our work contributes to the growing area of study of post-translational protein alteration by ubiquitin-like modifiers. A greater understanding of the protein handling that occurs during leukemic cell differentiation might allow us to modulate these processes and broaden the application of differentiation therapy for the improved treatment of AML. 
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Supporting Information
Supplementary Figure 1 ISGylation – In the first step of ISGylation ISG15 is activated by the E1 enzyme UBE1L in an ATP dependent reaction. ISG15 is then transferred to the E2 UBE2L6 and subsequently to a target through an E3 enzyme such as HERC5. USP18 is an ISG15 specific isopeptidase which reverses this coupling. 
Figure Legends
Figure 1. UBE2L6 expression is increased during leukemic cell differentiation. (A) 
UBE2L6 mRNA levels of primary AML patient samples, normal CD34+(HSC) cells and mature granulocytes from healthy donors were quantified using qPCR. The relative ΔCt expression was calculated by the difference of UBE2L6 expression to the housekeeping genes HMBS and 
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Figure 2. UBE2L6 inhibition attenuates APL cell differentiation. NB4 cells expressing non-targeting shRNA (SHC) or shRNA targeting UBE2L6 (shUBE2L6_499 and shUBE2L6_1082) were seeded at 0.2 x 105 cells/mL and treated for 72h with 1μM ATRA. (A) Functional knockdown efficiency was tested by measuring UBE2L6 protein levels in whole cell lysates by immunoblot at 72h.  β-actin was used as a loading control. (B) Total RNA was extracted and differentiation was assessed by measuring GCSFR mRNA expression by qPCR. Values are given as n-fold induction compared to untreated cells and normalized to housekeeping gene HMBS (n=3) (t-test ***p ≤ 0.001, *p ≤ 0.05). (C) Surface CD11b protein expression on live cells was measured by flow cytometry as a second assay of differentiation. Median fluorescence intensities (MFIs) are shown at 72h (n=3) (t-test **p ≤ 0.01). (D) Morphologic appearance of treated cells at 72h. Neutrophil differentiation evidenced by increased cytoplasmic volume and nuclear lobulation, indicated with arrows. (E) Neutrophil function was tested using NBT at 72h (i) Differentiated cells reduce NBT to a blue colour. (ii) NBT positive cells were counted in triplicate and presented as mean ± S.E.M (t-test **p ≤ 0.01, *p ≤ 0.05)(Magnification 400X).
Figure 3. UBE2L6 regulates ATRA-induced ISGylation. (A) Proteins known with a high confidence to interact with UBE2L6 are shown. Image created using the STRING proteomics database (www.string-db.org). (B) Levels of free and conjugated ISG15 was measured by immunoblot in whole cell lysates extracted from NB4 cells expressing either non-targeting shRNA (SHC) or shRNA targeting UBE2L6 (shUBE2L6_499 and shUBE2L6_1082) following a 72h treatment with 1μM ATRA. β-actin was used as a loading control. 
Figure 4. ISG15 expression is induced during leukemic cell differentiation. (A) NB4 and NB4R cells were seeded at 0.2 x 105 cells/mL and treated with 1μM ATRA for 72h. Successful differentiation was confirmed in NB4 cells by flow cytometric analysis of CD11b expression. ATRA-resistant NB4R cells did not differentiate (data not shown). Total RNA was extracted and ISG15 mRNA expression was quantified by qPCR. Values are given as n-fold induction compared to untreated cells and normalized to housekeeping gene hPRT (n=3) (t-test ****p 
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HL60R cells failed to differentiate (data not shown). Total RNA was extracted and ISG15 expression was quantified by qPCR. Values are given as n-fold induction compared to untreated cells and normalized to housekeeping gene HMBS (n=3) (t-test **p ≤ 0.01). 
Figure 5. Inhibition of ISG15 impedes APL cell differentiation. NB4 cells expressing non-targeting shRNA (SHC) or shRNA targeting ISG15 (shISG15_319 and shISG15_352) were seeded at 0.2 x 105 cells/mL and treated for 72h with 1μM ATRA. (A) Functional knockdown efficiency was tested by measuring protein levels of both free and conjugated ISG15 in whole cell lysates by immunoblot at 72h.  β-actin was used as a loading control. (B) Total RNA was extracted and differentiation was assessed by measuring GCSFR mRNA expression by qPCR. Values are given as n-fold induction compared to untreated cells and normalized to housekeeping gene HMBS (n=3) (t-test ****p ≤ 0.0001, ***p ≤ 0.001). (C) Surface CD11b protein expression on live cells was measured by flow cytometry as a second assay of differentiation. Median fluorescence intensities (MFIs) are shown at 72h (n=3) (t-test *p ≤ 0.05). (D) Morphologic appearance of treated cells at 72h. Neutrophil differentiation evidenced by increased cytoplasmic volume and nuclear lobulation, indicated with arrows. 
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Table 1. ATRA-induced expression changes in ISGylation genes  
 
Gene Name Fold Change in 
Expression  
UBE2L6 Ubiquitin-conjugating enzyme E2L6  200.93 
ISG15 Interferon-stimulated gene 15 17.54 
USP18 Ubiquitin specific peptidase 18 12.53 
UBE1L Ubiquitin-like modifier activating enzyme 7 7.77 
HERC5 HECT and RLD domain containing E3 ubiquitin 
protein ligase 5 
3.62 
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